Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Significantly increase the vaccination rate among the elderly: Livzon's COVID-19 vaccine (CHO cell) is here!
Published Time：
2023-02-23
The overall national epidemic prevention and control situation is improving, and has smoothly entered the normalized prevention and control stage of "Class B and Class B management." However, the global epidemic is still prevalent, and the virus continues to mutate.
According to CCTV News, the Standing Committee of the Political Bureau of the CPC Central Committee held a meeting on February 16 to hear a report on the recent COVID-19 epidemic prevention and control work. The meeting proposed that, based on virus mutations and vaccine protection, the next stage of vaccination work should be scientifically planned to promote a sustained increase in vaccination rates among the elderly, etc.
In December 2022, the State Council's Joint Prevention and Control Mechanism for the Novel Coronavirus Pneumonia Epidemic issued the "Implementation Plan for the Second Booster Immunization of COVID-19 Vaccines" (hereinafter referred to as the "Plan"), and the Recombinant Novel Coronavirus Fusion Protein Vaccine (CHO cells) developed by Lizhu Bio was selected as an optimal combination.
This vaccine is the world's first phase III clinical trial to prove that it can effectively prevent Omicron. Lizhu Bio's Recombinant Novel Coronavirus Fusion Protein Vaccine (CHO cells) is domestically developed in China and has an innovative fusion protein molecular design with independent intellectual property rights. The IFNa-Pan-RBD-Fc fusion protein molecule, innovatively designed by the CAS and Lizhu Bio domestic teams, incorporates biological adjuvants and other immune active components on the basis of other recombinant protein vaccines, significantly improving the level of virus neutralizing antibodies.
Clinical trial data show that after sequential strengthening, the absolute protective efficacy of the vaccine against Omicron mild and above symptomatic infections (relative to the unvaccinated population) is 61.35%, which is comparable to the effect of the third booster shot of mRNA vaccines, whether homologous or heterologous. However, the incidence of adverse reactions such as injection pain is about one-tenth that of mRNA vaccines, and the overall safety is good.
Lizhu Group (000513.SZ) stated in an institutional research meeting that infection + vaccine mixed immunity is crucial and can better prevent different variants. The latest research shows that for every additional vaccine dose, the risk of transmission after infection is reduced by 11%, but this effect weakens with the extension of the interval after immunization, so vaccination remains an effective means of preventing secondary infection, reducing mortality, severity, and hospitalization rates.
Lizhu Bio's Recombinant Novel Coronavirus Fusion Protein Vaccine (CHO cells) has become one of the preferred options for the general public due to its good safety and protective efficacy. The "Plan" states that sequential booster immunization should be prioritized, or vaccines containing Omicron strains or with good cross-immunity to Omicron strains should be used for the second booster immunization, with preferred combinations including 3 doses of inactivated vaccines + 1 dose of Lizhu Bio's Recombinant Novel Coronavirus Fusion Protein Vaccine (CHO cells). It also emphasizes that the second booster immunization can be carried out on the basis of the first booster immunization in high-risk groups, people over 60 years old, people with serious underlying diseases, and people with low immunity.
It is worth noting that the protective efficacy of Lizhu Bio's Recombinant Novel Coronavirus Fusion Protein Vaccine (CHO cells) for people with underlying diseases is as high as 71.83%, and the protective efficacy for people over 60 years old or with underlying diseases is 61.19%, demonstrating its protective efficacy advantage for key populations such as people with underlying diseases, the elderly, and high-risk groups.
In addition to vaccines, Lizhu provides another "weapon" for the treatment of severe COVID-19 patients: Tocilizumab Injection (trade name: Anvita). At the end of last year, the term "white lung" attracted much public attention, especially among the elderly. The "Expert Recommendations on Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variants" clearly points out that Tocilizumab, an IL-6 antagonist, can inhibit the excessive inflammatory response in severe patients. In January 2023, Lizhu Group's Tocilizumab Injection was approved for listing by China's drug administration, which will provide effective treatment drugs and solutions for severe COVID-19 patients. From vaccination to severe treatment, Lizhu provides safer and more effective protection for the elderly!
Source: Sohu.com
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.